

POSTER LISTING

284 posters have been successfully accepted for this year's 18th ISoP Annual Meeting. Posters will be displayed in the exhibition hall area with half of the posters being displayed on Monday and half on Tuesday.

Poster judging will take place during the conference and the three best posters will be awarded during the poster prize ceremony on Wednesday 14 November 16:00 – 16:15.

Presenting authors are kindly requested to be present throughout the official poster viewing times (as specified above) but due to the large number of posters, the Poster Committee will not only view the posters during the official

sessions but during the conference on Monday and Tuesday.

Official poster session times are:

Date	Time
Monday 12 November	10.45 - 11.15 15.30 - 16.00
Tuesday 13 November	09.45 - 10.00 15.30 - 16.00

Assistance for poster mounting / dismantling will be available at the Poster desk located in the exhibition hall area.

SESSION 1 POSTER PRESENTATION MONDAY 12 NOVEMBER

Benefit-Risk Assessment And Risk Management In Pharmacovigilance

Poster No. | Abstract Paper Title Presenter

1	ISoP18-1436 Planning For Implementation Of A Structured Benefit-Risk Framework Within Industry Abimbola Cole, Takeda Pharmaceuticals, United States
2	ISoP18-1125 The Impact Of A Restrictive Regulatory Action On The Utilization Of Pregabalin Containing Products In Saudi Arabia Amal Alshatri Almotiry, Saudi Food and Drug Authority (SFDA), Saudi Arabia
3	ISoP18-1074 Objectives And Design Of The Post-Authorization Studies Evaluating The Effectiveness Of The Risk Minimization Measures In The Eu Pas Register Andreea Farcas, University of Medicine and Pharmacy Cluj-Napoca, Romania
4	ISoP18-1086 Process Indicators Vs. Correlated Endpoints In Studies Evaluating The Effectiveness Of Risk Minimization Measures In The Eu Pas Register Andreea Farcas, University of Medicine and Pharmacy Cluj-Napoca, Romania

5	ISoP18-1087 A Description Of Medicines Associated Safety Issues Evaluated Through A Referral Procedure At The Eu Level Andreea Farcas, University of Medicine and Pharmacy Cluj-Napoca, Romania
6	ISoP18-1298 Cast Analysis Of Uk Pregnancies Reported During/After Isotretinoin Administration. Proposal For Application In A Global Safety Study. Brian Edwards, NDA Regulatory Science LTD, United Kingdom
7	ISoP18-1477 Risk Factors Contributing To Insulin Prescription Errors In A Public Tertiary Care Hospital In Sub Saharan Africa Dorothy Atieno Aywak - Aloyo, Kenyatta National Hospital, Kenya
8	ISoP18-1437 Management Of Medication Errors In Pharmacovigilance Centres: Case Of Morocco Ghita Benabdallah, CAPM WHO CC, Morocco
9	ISoP18-1032 Analysis Of The Risk Management Plans Submitted To The Rational Drug Use And Pharmacovigilance Department At Jfda (2014-2017) Jaber Jaber, Jordan food and drug administration, Jordan
10	ISoP18-1303 Consideration Of Benefit-Risk Assessment And Risk Management In Clinical Research Of Traditional Medicines Li Zhang, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, China
11	ISoP18-1174 A Comparison Of Safety-Related Label Changes For Medicines With And Without Major Objections At Time Of Marketing Authorisation Lourens Bloem, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Dutch Medicines Evaluation Board, Netherlands
12	ISoP18-1085 Risk Minimization Measures Of A Paediatric Orphan Drug For Treatment Of Neonatal Diabetes Manon Exposito, AMRING, France
13	ISoP18-1404 Practical Aspects Of Developing Relevant Key Performance And Quality Indicators For Risk-Based Quality Management In Pharmacotherapy. Marina Alexandrovna Malikova, Boston University, Boston Medical Center, United States
14	ISoP18-1222 In Vivo Tests For Investigating Immediate Hypersensitivity To General Anesthetics Mehdi Bouhlel, Tunisian National Centre of Pharmacovigilance, Tunisia
15	ISoP18-1177 A Review Of Benefit-Risk Assessment Over The Product Lifecycle Milena Miljkovic, PrimeVigilance, Serbia

POSTER LISTING

16	ISO P18-1183 The Association Between Inappropriate Medication Use And Health-Related Outcomes Among Nursing Home Residents: A Systematic Review And Meta-Analysis Pajaree Mongkhon, Faculty of Pharmaceutical Sciences, Naresuan University, University of Phayao, Thailand
17	ISO P18-1152 Is The Risk Of Linezolid To Cause Serotonin Syndrome Real In Routine Clinical Practice ? Paul M. Tulkens, Université catholique de Louvain, Belgium
18	ISO P18-1341 Anticoagulant Therapy In Patients With Atrial Fibrillation And Risk Of Bleeding: Interim Analysis - Tyrion Study Sara Ferraro, University of Pisa, Italy
19	ISO P18-1130 Assessment Of Cyclosporine Blood Concentrations In Adults With Aplastic Anemia Riadh Daghfous, Clinical and Experimental Pharmacology Research Laboratory LR16SP02, National Pharmacovigilance center, Tunisia
20	ISO P18-1386 Safety And Efficacy Of Tolvaptan In The Suisse Adpkd Cohort Stefan Russmann, drugsafety.ch, Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland, Clinic Hirslanden, Boston University School of Public Health, United States

Global Pharmacovigilance

21	ISO P18-1331 Drug-Induced Anaphylaxis In French And Vietnamese Pharmacovigilance Database 2010-2015: A Social Pharmacology Discussion Jean-Louis Montastruc, Centre Hospitalier Universitaire, Faculté de Médecine de l'Université Paul-Sabatier, France
23	ISO P18-1504 Toxic Epidermal Necrolysis Related To Lamotrigine: About A Case Amina Tebaa, Moroccan center of pharmacovigilance, Morocco
24	ISO P18-1364 Thyroid Dysfunction After Long-Term Treatment By Amiodarone Amina Tebaa, Poison and pharmacovigilance center of Morocco, Morocco
25	ISO P18-1510 Development Of Inhibitors In Hemophils A: About Four Case Amina Tebaa, Moroccan center of pharmacovigilance, Morocco

26	<p>ISoP18-1202</p> <p>Reporting Of Qt Interval Prolongation And Torsade De Pointe For Hiv-Antiretrovirals In Vigibase: Focus On Potential Drug-Drug Interactions</p> <p>Anne Simon, Swiss Tropical and Public Health Institute, University of Basel, Switzerland</p>
27	<p>ISoP18-1362</p> <p>Ecopharmacovigilance For Better Health In Ghana</p> <p>Cynthia Amaning Danquah, Kwame Nkrumah University of Science and Technology, Ghana</p>
28	<p>ISoP18-1064</p> <p>Pharmacovigilance In Emerging Markets: An Industry Initiative To Strengthen Global Engagement And Support</p> <p>Esteban Herrero Martinez, AbbVie, United Kingdom</p>
29	<p>ISoP18-1129</p> <p>Spontaneous Reporting Of Suspected Adverse Drug Reactions In Patients With Arthritis: A Scoping Literature And Data Review</p> <p>Gary Greer, University of Oxford, United Kingdom</p>
30	<p>ISoP18-1078</p> <p>Tamoxifen And The Risk Of Parkinsonism: A Case Non-Case Study</p> <p>Jean-Louis Montastruc, Faculté de Médecine - Centre Hospitalier Universitaire, France</p>
31	<p>ISoP18-1118</p> <p>Risk Of Diabetes Associated With Statins Fibrates And Their Association</p> <p>Jean-Louis Montastruc, Faculté de Médecine, France</p>
32	<p>ISoP18-1119</p> <p>Fluoroquinolones And Aortic Aneurysms: What Are The Fluoroquinolones At Risk?</p> <p>Jean-Louis Montastruc, Faculte de Medecine, France</p>
33	<p>ISoP18-1324</p> <p>Retrospective Study On Cutaneous Adverse Drug Reactions Induced By Antiepileptic Drugs</p> <p>Latifa Ait Moussa, cNtre Antipoison et de Pharmacovigilance du Maroc, Morocco</p>
34	<p>ISoP18-1372</p> <p>Serious Adverse Drug Reactions: Experience From The Moroccan Pharmacovigilance Centre</p> <p>Latifa Ait Moussa, Centre Antipoison et de Pharmacovigilance du Maroc, Morocco</p>
35	<p>ISoP18-1221</p> <p>Drug Sefty : In-Vitro Study Of Physicochemical Incompatibilities Of Injectable Antibiotics Used In Pediatrics With Other Drugs In An Infusion</p> <p>Mustapha Bouatia, University Mohamed V, Rabat, Morocco</p>
36	<p>ISoP18-1359</p> <p>Drug Sefty : Drug Incompatibilities In Intensive Care</p> <p>Mustapha Bouatia, University Mohamed V, Rabat, Morocco</p>

POSTER LISTING

37	ISoP18-1256 Acetylsalicylic Acid Adverse Events: A Survey Of General Practitioners In Democratic Republic Of Congo Odette Mapipi Mboma, University of Kinshasa, Congo, The Democratic Republic of the
38	ISoP18-1151 Psychiatric Adverse Drug Reactions With Anti-Hypertensive Treatment: Review & Analysis Of Smpcs Pipasha Biswas, Symogen Limited, United Kingdom
39	ISoP18-1224 Comparison Of 4 Commonly Prescribed Antipsychotics Patient Information Leaflets Of Indian Companies With The Original Smpc From Innovator Companies Pipasha Biswas, Symogen Limited, United Kingdom
40	ISoP18-1460 Factors Associated With Serious Medication Errors In Moroccan Pharmacovigilance Database From 2006 To 2016 Rachida Soulaymani Bencheikh, Centre Anti Poison et de Pharmacovigilance du Maroc, Morocco
41	ISoP18-1254 Adverse Drug Reaction Reports Following A "Brand Switch". The New Zealand Experience. Rhiannon Braund, University of Otago, New Zealand

Miscellaneous

42	ISoP18-1165 Social Media: The Battleground For Public Opinion On Medicines Safety Alexandra Hoegberg, Uppsala Monitoring Centre, Sweden
43	ISoP18-1354 Reporting Immune Related Adverse Events During Checkpoint Inhibitor Therapy Anne Leuppi-Taegtmeier, University Hospital Basel, University Hospital Basel, Switzerland
44	ISoP18-1264 Adherence To Treatment Of Chronic Patients In General Practitioner Office-First Results Of A Cross-Sectional Survey Camelia Bucsa, "Iuliu Hatieganu" University of Medicine and Pharmacy, Romania
45	ISoP18-1144 An Example Of Qualitative Signal Detection Within The French Signal Management Process Claire Ferard, ANSM, France

46	<p>ISoP18-1497</p> <p>Risk Perception Of Adverse Drug Reactions By Health Students – Influence Of Undergraduate Education</p> <p>Cristiano Matos, Coimbra Health School, Portugal, Faculty of Pharmacy, University of Seville, Spain</p>
47	<p>ISoP18-1416</p> <p>Reducing Prescribing Errors Associated With In-Patient Electronic Prescribing Systems: An Investigation Of Pharmacist Interventions</p> <p>Fahad Alshahrani, University of Birmingham, United Kingdom</p>
48	<p>ISoP18-1412</p> <p>Exploring Health Professionals Perceptions About Drug Related Problems In Older Patients</p> <p>Fátima Roque, Research Unit for Inland Development, Polytechnic Institute of Guarda (UDI/IPG), Portugal</p>
49	<p>ISoP18-1297</p> <p>Impact Of The Doctor-Patient Relationship On Non-Compliance With Pharmacological Medical Prescription In Chronic Disease. A Cross-Sectional Study</p> <p>Fátima Roque, Research Unit for Inland Development (UDI/IPG), Health Sciences School, Polytechnic of Guarda (ESS/IPG), Portugal</p>
50	<p>ISoP18-1299</p> <p>Factors Of Non-Adherence To Therapy In Chronic Patients With Pathologies Covered By Specific Legislation In Portugal</p> <p>Fátima Roque, Research Unit for Inland Development (UDI/IPG), Health Sciences School, Polytechnic of Guarda (ESS/IPG), Portugal</p>
51	<p>ISoP18-1280</p> <p>Nurses' Experiences, Attitudes And Perspectives About Adrs And Reporting In The Netherlands</p> <p>Gerda Weits, Netherlands Pharmacovigilance Centre Lareb, Netherlands</p>
52	<p>ISoP18-1098</p> <p>Awareness Survey On Drug-Drug Interactions Among Argentinean Health Care Professionals</p> <p>Guadalupe Darderes, GADOR S.A., Argentina</p>
53	<p>ISoP18-1117</p> <p>Pvknow: A Pharmacovigilance Knowledge Management System</p> <p>Jeltje Boer, Netherlands Pharmacovigilance Centre Lareb, Netherlands</p>
54	<p>ISoP18-1282</p> <p>The Impact Of Facilitated Reporting Of Adverse Drug Reactions By Health Care Professionals As A New Source Of Adr Information</p> <p>Jette van Lint, Netherlands Pharmacovigilance Centre Lareb, Netherlands</p>
55	<p>ISoP18-1133</p> <p>Framework For Analyzing Consumer Health Questions</p> <p>Joyce Cao, Herbalife Nutrition, United States</p>
56	<p>ISoP18-1495</p> <p>Overview Of Adverse Reactions (Adrs) For Elderly Patients Reported In 2017 In Croatia</p> <p>Katarina Gvozdanovic, Agency for Medicinal Products and Medical Devices of Croatia, Croatia</p>

POSTER LISTING

- | | |
|----|--|
| 57 | ISoP18-1272
Comparison Of Reported Adverse Events Of Premature And Term Born Infants Following Childhood Vaccinations In The Netherlands
Leontine van Balveren, Netherlands Pharmacovigilance Centre Lareb, Netherlands |
| 58 | ISoP18-1094
Expectedness Of Antimicrobials Adverse Drug Reactions In Iraq, 2010-2017
Manal Mohammed Younus, MOH, Iraq |
| 59 | ISoP18-1185
Process Characteristics And Time To Follow-Up Of Adverse Drug Reaction Reports From A Single Center: A Retrospective Analysis
Matthias Ganso, Department of Medicine, ABDA - Federal Union of German Associations of Pharmacists, Germany |
| 60 | ISoP18-1420
Multiple Drugs Neosensitization Following Dress Syndrome Induced By Cotrimoxazole
Mehdi Bouhlel, Tunisian National Centre of Pharmacovigilance, Tunisia |
| 61 | ISoP18-1488
Cetuximab-Induced Acneiform Eruption Resistant To Doxycycline Preventive And Curative Therapy
Mehdi Bouhlel, Tunisian National Centre of Pharmacovigilance, Tunisia |
| 62 | ISoP18-1489
Cerolizumab Pegol-Induced Palmoplantar Pustulosis
Mehdi Bouhlel, Tunisian National Centre of Pharmacovigilance, Tunisia |
| 63 | ISoP18-1334
Impact Of Quality And Outcomes Framework On Prevalence Of Chronic Kidney Disease In United Kingdom
Moninder Kaur, Cognizant Technology Solutions, United Kingdom |
| 64 | ISoP18-1377
Adverse Drug Reactions Arising From The Use Of The Products Outside The Terms Of The Marketing Authorisation
Nikica Mirošević Skvrce, Agency for Medicinal Products and Medical Devices, Croatia |
| 65 | ISoP18-1066
What German Physicians Think About The Spontaneous Reporting System And How They Would Change It. Results Of An Online Survey
Thomas Stammschulte, Drug Commission of the German Medical Association, Germany |

Patient Involvement In Pharmacovigilance

66	ISoP18-1187 Contribution Of Patient'S Reports In Signal Detection: Experience Of A Pharmacovigilance Center Agnès LILLO-LE LOUET, Pharmacovigilance Hopital Européen Georges Pompidou, France
67	ISoP18-1509 Lyell Syndrome With Carbamazépine And Amoxicilline: Clinical Case Amina Tebaa, Poison and pharmacovigilance center, Morocco
68	ISoP18-1307 Understanding Paediatric Patients' Pharmaceutical Needs Post Discharged From A Hospital: An Exploration Study Asia Rashed, King's College London, Evelina London Children's Hospital, Guy's & St Thomas' NHS Foundation Trust, United Kingdom
69	ISoP18-1263 Patient Reporting Of Adverse Drug Reactions In Romania-Pilot Phase Of A Cross-Sectional Survey Camelia Bucsa, "Iuliu Hatieganu" University of Medicine and Pharmacy, Romania
70	ISoP18-1250 Contribution Of Patients To Pharmacovigilance – The Views Of European Patient Organizations Cristiano Matos, Faculty of Pharmacy, University of Seville, Spain, Coimbra Health School - IPC, Portugal
71	ISoP18-1128 Monitor The Benefit And Risk Of Medicines In Primary Care; Building A Bridge Between Daily Practice And Research Eugene van Puijenbroek, Netherlands Pharmacovigilance Centre Lareb, University of Groningen, Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, - Epidemiology & -Economics, Netherlands
72	ISoP18-1430 What Think Older Patients About Their Medicines? Fátima Roque, Research Unit for Inland Development, Polytechnic Institute of Guarda (UDI/IPG), Portugal
73	ISoP18-1345 Consumers' Contributions To Pharmacovigilance For Herbal Medicines –Analyses Of Global Reports In Vigibase© Florence Van Hunsel, The Netherlands Pharmacovigilance Centre Lareb, Netherlands
74	ISoP18-1415 Patient Knowledge Of Adverse Drug Reaction Reporting Karamjit Badyal, West Midlands Centre for Adverse Drug Reactions, University of Birmingham, United Kingdom
75	ISoP18-1467 Active Surveillance Of Adverse Events Following Immunization (Aefi) Using Both Paper Forms And Sms Laura Gonella, University of Verona, Italy

POSTER LISTING

76	ISoP18-1101 The Degree Of Impact Of Adverse Drug Reactions As Experienced By Patients Michelle Haaksman, Netherlands Pharmacovigilance Centre Lareb, Netherlands
77	ISoP18-1068 An Ecological Study On Consumer Adverse Event Reporting To The Us Food And Drug Administration Monica Munoz, US Food and Drug Administration, University of Florida, United States
78	ISoP18-1496 A Mysterious Resistance To Acenocoumarol! Riadh Daghfous, Centre National de Pharmacovigilance, Tunisia
79	ISoP18-1492 Adverse Drug Reactions Leading To Ocular Surface Disease Clinic Visits At An Eye Hospital: A Brief Report Safa Alizadeh, Tehran University of Medical Sciences, Iran, Islamic Republic Of
80	ISoP18-1053 The Moroccan Phytovigilance System: An Experience Of Involving Patients From 2012 To 2016 Souad Skalli, Faculty of Sciences, Mohammed V University In Rabat, Morocco
81	ISoP18-1056 Chronic Disease Sufferers' Willingness To Participate In Spontaneous Adverse Drug Reaction Reporting System Violeta Getova, Medical University of Plovdiv, Bulgarian drug agency, Bulgaria

Pharmacovigilance And The Pharmaceutical Industry

82	ISoP18-1320 The Impact Of Pharmacovigilance Oversight On Expanded Access Programs (Eaps) With Nivolumab In Bristol-Myers Squibb Turkey Belce Cilmi Arslan, Bristol-Myers Squibb Ilacları Inc. Istanbul, Turkey, Turkey
83	ISoP18-1021 Developing A New Methodology For Preparing A Guideline: The Case Of Good Pharmacovigilance Outsourcing Practices Brian Edwards, ACRES, United Kingdom
84	ISoP18-1216 Pharmacovigilance In Bioequivalence Studies: Is There A Difference In The Prevalence Of Adverse Events Between Original And Generic Medicines ? Mustapha Bouatia, Mohammed V University, Faculty of Medicine and Pharmacy, Morocco

Pharmacovigilance in Resource-Limited Countries

85	ISoP18-1279 Serious Adverse Drug Reaction Reports In The Nigerian Vigiflow Database From September 2004 To December 2016 Ali Ibrahim, NAFDAC, Nigeria
86	ISoP18-1173 Vaccine Safety Surveillance In Pregnancy Using Gaia Definitions For Neonatal Conditions: A Feasibility Assessment In Low- And Middle-Income Countries Anke L. Stuurman, P95 Epidemiology and Pharmacovigilance Consulting and Services, Belgium
87	ISoP18-1505 The New Pharmacovigilance Guidance In India- Diluted Wine In A Borrowed Bottle Anupama Ramkumar, Arkus Research Pvt Ltd, India
88	ISoP18-1400 Management Of Individual Case Safety Reports From Multiple Source In The Drc National Pharmacovigilance Center ARNOLD NSEKA ZI NSEKA, National Pharmacovigilance Center, Congo, The Democratic Republic of the
89	ISoP18-1267 An Online Collaborative, Open Access Pharmacovigilance Platform For Resource-Limited Countries Elizabeth Allen, University of Cape Town, South Africa
90	ISoP18-1161 Online Availability Of Regulatory Documents, Safety Information And Adverse Drug Reaction Reporting In African Countries Hanneke Dominicus, Dominicus Medicus Consultancy, Consortium for African Regulatory expertise Development, Netherlands
91	ISoP18-1045 Drug- Or Herb- Induced Liver Injury In China Jia-Bo Wang, Beijing 302 Hospital of China, China National Advisory Council of Traditional Chinese Medicines-Induced Liver Injury, China
92	ISoP18-1403 Pharmacovigilance Intensive During The Administration For Perfusion Of Non-Innovative Rituximab In The Rebagliati Hospital From March To June 2015 Liz Aliaga, Hospital Rebagliati- EsSalud, Peru
93	ISoP18-1517 Surveillance Of Anti-Tuberculosis Drugs In Thailand Pakawadee Sriphiromya, Ministry of Public Health, Thailand
94	ISoP18-1252 Present Status And Future Prospects Of Pharmacovigilance In Nepal Renu Karki, Pokhara University, Nepal

POSTER LISTING

95	ISoP18-1507 Pharmacovigilance System In Arabic Countries: A Systematic Review Of 22 Arab Countries Thamir Alshammari, University of Hail, Saudi Food and Drug Authority, Saudi Arabia
96	ISoP18-1232 The Experience Of Using Khartoum Medicines Information Center (Khmic) As A Focal Point To Enhance Pharmacovigilance In Sudan Tsneem Yousef, Ministry of Health Khartoum State, Sudan
97	ISoP18-1262 Opinion Of Costa Rican Pharmacists Regarding A New Adverse Drug Reaction Reporting Platform, 2017 Victoria Hall Ramirez, University of Costa Rica, Costa Rica
98	ISoP18-1140 Factors Influencing Low Adverse Drug Reaction Reporting Among Healthcare Professionals In Ghana Walter-Rodney Nagumo, University Of Sheffield, United Kingdom
99	ISoP18-1512 Implementation Of Medication Errors Reporting Tools In Two Teaching Hospitals In Kinshasa Yves Lula, University of Kinshasa/National Pharmacovigilance Centre, Congo, The Democratic Republic of the
99.a	ISoP18-1054 Frequency Of Regulatory Breach Of Risk Management Plans In Mexico. Octavio Alejandro Enríquez Lara, Federal Comission for Health Risks Protection, Mexico
99.b	ISoP18-1443 Use Of Pharmacovigilance Data Mining For Signal Detection In The Mexican Pharmacovigilance National Center Spontaneous Reports Database. Raymundo Castillo Del Valle, Federal Comission for Health Risks Protection, Mexico

Pharmacovigilance Of Medical Devices

100	ISoP18-1321 Reporting Point Side Effects Medical Implants: Experiences After One Year Carolina Molto-Puigmarti, RIVM, Meldpunt en Expertisecentrum Bijwerkingen Implantaten, Netherlands
101	ISoP18-1035 Herpes Simplex Virus Encephalitis After Deep Brain Stimulation For Epilepsy: A Case-Report Marylaure GAVARD, Grenoble Alpes University Hospital, France
102	ISoP18-1219 Dress Syndrome Associated With Diclofenac Ons Charfi, National Centre of Pharmacovigilance of Tunisia, Tunisia

103	ISoP18-1220 Doxycycline Induced Generalized Bullous Fixed Drug Eruption: 2 Case-Reports Ons Charfi, National Centre of Pharmacovigilance of Tunisia, National Centre of Pharmacovigilance of Tunisia, National Centre of Pharmacovigilance of Tunisia, Tunisia
104	ISoP18-1309 Apipuncture Induced Urticaria With Recurrence Following Honey Contact Ons Charfi, National Centre of Pharmacovigilance of Tunisia, Tunisia
105	ISoP18-1318 Neosensitization To Multiple Drugs Following Carbamazepine Dress Syndrome. Ons Charfi, National Centre of Pharmacovigilance of Tunisia, Tunisia

Risk Communication In Pharmacovigilance

106	ISoP18-1439 Role Of Patient Information On The Adverse Effects Of Medicines In Oncology AMINA TEBAA, ministry of health, Morocco
107	ISoP18-1461 Media-Vigilance Moroccan Experience Amina Tebaa, Centre Antipoison et de Pharmacovigilance, Morocco
108	ISoP18-1154 Amusing Ourselves To Death: How Science And Reason Are Losing Their Grip In Public Discourse Bruce Peter John Hugman, Uppsala Monitoring Centre, Sweden, United Kingdom
109	ISoP18-1483 Drug Safety Alert - Time To Action Christopher Anton, West Midlands Centre for Adverse Drug Reactions, United Kingdom
110	ISoP18-1227 Pharmacists' Role In Risk Communication On Self-Medication – Pilot Study From Bulgaria Hristina Viktorova Lebanova, Faculty of Pharmacy, Medical University-Pleven, Bulgaria
111	ISoP18-1462 Iatrogenic Adrenal Insufficiency Following Use Of Corticosteroids In Hiv Infected Patients Receiving Cobicistat-Based Antiretroviral Regimen Roseline Ing-Lorenzini, Hôpitaux Universitaires de Genève, Switzerland, Switzerland
112	ISoP18-1481 Signal Detection And Risks Communication In Pharmacovigilance For Cardiovascular Clinical Trials. Marina Alexandrovna Malikova, Boston University, Boston Medical Center, United States
113	ISoP18-1097 High Dose Methotrexate Delayed Elimination: A Case Series. Thierry TRENQUE, Reims University Hospital, France

POSTER LISTING

Signal Detection

- | | |
|-----|---|
| 114 | ISoP18-1092
Doxycycline Associated Fixed Drug Eruptions Safety Review
Abdulaziz Alakeel, Saudi Food and Drug Authority, Saudi Arabia |
| 115 | ISoP18-1146
Alopecia Occurred With Infliximab: What Link? Clinical Case
Amina Tebaa, Poison and pharmacovigilance center of Morocco, Morocco |
| 116 | ISoP18-1178
Cognitive Patterns In Pharmacovigilance Assessments
Birgitta Grundmark, Uppsala Monitoring Centre, Uppsala University, Sweden |
| 117 | ISoP18-1326
Safety Profile Of Sodium-Glucose Co-Transporter-2 (Sglt2) Inhibitors: A Retrospective Study Of The Portuguese Pharmacovigilance System Database
Diogo Mendes, AIBILI, Portugal |
| 118 | ISoP18-1080
Characterization And Disproportionality Analysis Of Spontaneously Reported Cases Of Medication Errors To The U S-F D A Adverse Event Reporting System
Faizan Mazhar, Università di Milano, Milan, Italy, Italy |
| 119 | ISoP18-1409
Detecting A Potential Signal Of Quetiapine Abuse Using The Faers Database And Big Data Search Analytics
Georgios Papazisis, School of Medicine, Aristotle University of Thessaloniki, Greece |
| 120 | ISoP18-1311
Qualitative Method To Detect Signals And Manage Alerts In Pharmacovigilance "From Identification To Actions"
Houda Sefiani, CAPM, R.CC, Morocco |
| 121 | ISoP18-1269
Exploring The Association Between Monoclonal Antibodies And Depression And Suicidal Ideation And Behavior: A Vigibase Study
Lotte Minnema, Utrecht Institute for Pharmaceutical Sciences (UIPS), Medicines Evaluation Board, Netherlands |
| 122 | ISoP18-1110
Who'S At Risk? Identifying Risk Groups For Adverse Drug Reactions Using Vigibase
Lovisa Sandberg, Uppsala Monitoring Centre, Sweden |

123	ISoP18-1123 Drospirenone And Its Association With Gall Bladder Diseases: A Retrospective Study Of Canadian Adverse Drug Reaction Monitoring Program , 1965-2017 Manan Shah, Nirma University, India
124	ISoP18-1401 From Clinical Trial To Post-Marketing Signal Management: A Continuum Margot Stam Moraga, IQVIA RDS AG, Switzerland
125	ISoP18-1171 Cox Selectivity And Chemical Subgroup Of Non-Steroidal Anti-Inflammatory Drugs And Frequency Of Spontaneous Reporting Of Hypersensitivity Reactions Olaf Klungel, Universiteit Utrecht, Universiteit Utrecht, Netherlands
126	ISoP18-1246 Signals Detection In Pharmacovigilance Based On The Seriousness Of Adverse Drug Reactions, Moroccan Pharmacovigilance Database, 2008-2017 Rachida Soulaymani-Bencheikh, Centre Anti Poison et de Pharmacovigilance du Maroc, Morocco
127	ISoP18-1135 Hepatotoxicity With A Natural Dietary Supplement, Artemisia Annu L. Extract In Grapeseed Oil. New Zealand Pharmacovigilance Centre Reports. Ruth Lesley Savage, University of Otago, New Zealand
128	ISoP18-1453 Importance Of Background Information Of The National Immunization Program For Children In Vaccine Signal Detection Wil Hilgersom, The Netherlands Pharmacovigilance Centre Lareb, Netherlands
129	ISoP18-1456 A Systematic Step-By-Step Approach To Vaccine Signal Detection Wil Hilgersom, The Netherlands Pharmacovigilance Centre Lareb, Netherlands

Teaching Pharmacovigilance

130	ISoP18-1138 Pharmacovigilance Awareness In Healthcare Professionals Emine Defne Aral Karakulak, Konya Beyhekim State Hospital, Turkey
131	ISoP18-1268 Pharmacovigilance Teaching To Undergraduates Of Medicine And Surgery School: The Experience Of Verona University Lara Magro, University of Verona, Italy
132	ISoP18-1315 Ten Years Of Experience In Graduate And Postgraduate Education In Pharmacovigilance Nikica Mirošević Skrcce, Agency for Medicinal Products and Medical Devices, Croatia
133	ISoP18-1302 Undergraduate Pharmacovigilance Education : Moroccan Experience Samira Serragui, Faculty of Medicine and Pharmacy, Morocco

POSTER LISTING

Women's Health, Including Contraceptive Medicines And Devices

134	ISoP18-1327 A Study Regarding The Frequency Of Adverse Reactions In The Infertility Treatment Anca Butuca, ULB Sibiu, Romania
135	ISoP18-1126 Outcomes Of Drug Exposition During Pregnancy: Analysis From A Teratology Information Service. Camille Lenoir, Geneva University Hospitals & Geneva University, Switzerland
136	ISoP18-1104 Gender Differences In Adverse Drug Reaction Reports; How Can They Be Explained? Eugene van Puijenbroek, Pharmacovigilance Centre Lareb, University of Groningen, Netherlands
137	ISoP18-1022 Fetal Effects Of Serotonin-Noradrenaline Reuptake Inhibitor Use During Pregnancy Florence Martin, Newcastle University, United Kingdom
138	ISoP18-1191 Pregnancies Associated With Etonogestrel Implants: Comparison Of Two Five-Year Reporting Periods Mira Harrison-Woolrych, ISoP, United Kingdom
139	ISoP18-1393 Massive Bilateral Pulmonary Embolism Induced By Estradiol Riadh Daghfous, Pharmacovigilance National Center, Tunisia. University Tunis El Manar, Tunisia
140	ISoP18-1406 Lichenoid Drug Eruption Induced By Levonorgestrel Riadh Daghfous, Pharmacovigilance National Center, Tunisia. University Tunis El Manar, Tunisia
142	ISoP18-1176 Antihypertensives Prescribed For Pregnant Women In Japan: Prevalence And Timing Determined From A Database Of Health Insurance Claims Tomofumi Ishikawa, Tohoku University Graduate School of Pharmaceutical Sciences, Japan